Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$596.92 USD
+3.13 (0.53%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $596.52 -0.40 (-0.07%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Medtronic (MDT) to Gain From Expanded Medicare Coverage for CGM
by Zacks Equity Research
CMS' expanded Medicare coverage includes continuous glucose monitors that can be integrated with Medtronic's (MDT) insulin pumps.
BD's (BDX) Latest Buyout to Enhance its Digital Capabilities
by Zacks Equity Research
BD's (BDX) acquisition of Scanwell is expected to significantly transform its at-home solutions both at present and in the future.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its potential in the Peripheral Intervention arm and a strong product portfolio.
Exact Sciences (EXAS) Rides on Cologuard Sales Amid COVID Fear
by Zacks Equity Research
Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Henry Schein's (HSIC) better-than-expected third-quarter results and robust performances by its operating businesses.
Here's Why You Should Retain Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) strong third-quarter performance and raised guidance.
Thermo Fisher Scientific (TMO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $651.70, marking a +0.99% move from the previous day.
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient-monitoring.
Zimmer Biomet (ZBH) Americas Business Slows Down Amid Pandemic
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to face COVID-induced challenges and market pressure.
Cerner's (CERN) Acquisition by Oracle to Boost Patient Outcome
by Zacks Equity Research
Cerner's (CERN) buyout is likely to aid in growing its community presence as well as improve patient outcomes.
STERIS (STE) Plans Sale of Non-Core Arm for Debt Repayment
by Zacks Equity Research
The latest spin-off of STERIS' (STE) Renal Care business is expected to partly reduce the company's debt burden.
3 Promising Gene Sequencing Stocks to Watch Out For in 2022
by Trina Mukherjee
Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.
Here's Why You Should Hold on to Medtronic (MDT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Medtronic's (MDT) better-than-expected earnings in the fiscal second quarter and robust performance of the Diabetes arm.
Here's Why You Should Add LabCorp (LH) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) strong third-quarter 2021 results and raised guidance.
Integra (IART) Businesses Rebound Despite Supply Issues
by Zacks Equity Research
Integra's (IART) ongoing sales recovery across geographies and product lines looks encouraging.
Avanos Medical (AVNS) Set to Acquire OrthogenRx for $160M
by Zacks Equity Research
Avanos Medical's (AVNS) deal to acquire OrthogenRx is likely to boost the company's chronic pain portfolio.
Here's Why You Should Invest in West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business.
Medtronic (MDT) Businesses Rebound Amid Raging Pandemic
by Zacks Equity Research
Medtronic (MDT) is registering strong organic growth in the Cardiovascular, Neuroscience and Diabetes segments on product launches.
Bruker (BRKR) Introduces JPK NanoWizard V for AFM Research
by Zacks Equity Research
Bruker's (BRKR) newly-introduced JPK NanoWizard V is expected to significantly contribute to life science atomic force microscopy investigations.
Edwards Lifesciences' (EW) SAPIEN 3 With Alterra Gets FDA Nod
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with severe pulmonary regurgitation.
Here's Why You Should Retain DexCom (DXCM) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.
Accuray's (ARAY) CyberKnife System Gets Shonin Approval
by Zacks Equity Research
Accuray's (ARAY) CyberKnife System can now be marketed in Japan post the Shonin approval.
Is Thermo Fisher Scientific (TMO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Thermo Fisher Scientific (TMO) and West Pharmaceutical Services (WST) have performed compared to their sector so far this year.
Here's Why You Should Hold on to Alcon (ALC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Alcon's (ALC) better-than-expected third-quarter results and robust performance by the Vision Care arm.